Furthermore, several small-molecule and antibody-based inhibitors of IGF1R and the PI3K/AKT/mTOR pathway are currently being tested in the clinic,55,56,57,58 highlighting the potential translatability of combining these drugs with BRAF/MEK inhibitor therapy for the treatment of melanoma LMD. This evidence concerns the gene BRAF and melanoma.